HDAC9 and nonpapillary renal cell carcinoma: TGF-β1 co-treatment with TSA significantly prevented TGF-β1-induced downregulation of E-cadherin and upregulation of collagen type I [242], suggesting that HDAC inhibitors may potentially be used in therapeutic approaches against EMT in ccRCC.